Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics


Navidea Biopharmaceuticals, Inc. (NAVB): $0.82

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NAVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NAVB Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for NAVB is -4.99 -- better than merely 2.17% of US stocks.
  • With a price/sales ratio of 46.17, Navidea Biopharmaceuticals Inc has a higher such ratio than 95.98% of stocks in our set.
  • As for revenue growth, note that NAVB's revenue has grown -41.91% over the past 12 months; that beats the revenue growth of only 3.97% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Navidea Biopharmaceuticals Inc, a group of peers worth examining would be SCYX, MYSZ, ONTX, AEIS, and GEOS.
  • Visit NAVB's SEC page to see the company's official filings. To visit the company's web site, go to www.navidea.com.

NAVB Valuation Summary

  • In comparison to the median Healthcare stock, NAVB's price/sales ratio is 1394.74% higher, now standing at 56.8.
  • NAVB's price/earnings ratio has moved down 11.9 over the prior 243 months.
  • NAVB's price/sales ratio has moved up 55.5 over the prior 243 months.

Below are key valuation metrics over time for NAVB.

Stock Date P/S P/B P/E EV/EBIT
NAVB 2021-08-31 56.8 8.7 -4.1 -3.8
NAVB 2021-08-30 56.8 8.7 -4.1 -3.8
NAVB 2021-08-27 56.1 8.6 -4.1 -3.7
NAVB 2021-08-26 55.0 8.4 -4.0 -3.6
NAVB 2021-08-25 54.0 8.3 -3.9 -3.6
NAVB 2021-08-24 56.1 8.6 -4.1 -3.7

NAVB Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 126.25%.
  • Its 3 year revenue growth rate is now at -93.51%.
  • Its 5 year price growth rate is now at -93.74%.
Over the past 34 months, NAVB's revenue has gone down $497,425.

The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.531513 -10.21815 -11.73093
2021-09-30 0.700416 -10.04659 -11.08244
2021-06-30 0.872423 -10.66532 -11.9495
2021-03-31 0.882478 -10.285 -11.67886
2020-12-31 0.915013 -8.173793 -11.38558
2020-09-30 0.815061 -8.350325 -11.15377

NAVB Stock Price Chart Interactive Chart >

Price chart for NAVB

NAVB Price/Volume Stats

Current price $0.82 52-week high $2.19
Prev. close $0.82 52-week low $0.72
Day low $0.82 Volume 15,700
Day high $0.85 Avg. volume 276,887
50-day MA $0.87 Dividend yield N/A
200-day MA $1.22 Market Cap 24.85M

Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio


Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.


NAVB Latest News Stream


Event/Time News Detail
Loading, please wait...

NAVB Latest Social Stream


Loading social stream, please wait...

View Full NAVB Social Stream

Latest NAVB News From Around the Web

Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma

DUBLIN, Ohio, February 07, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the University of Pennsylvania ("Penn") for a project to evaluate the use of Tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. The research is led by Principal

Yahoo | February 7, 2022

Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American

DUBLIN, Ohio, February 03, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur Life Sciences LLC ("Platinum-Montaur"), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportuni

Yahoo | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 22, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | December 16, 2021

Read More 'NAVB' Stories Here

NAVB Price Returns

1-mo -17.17%
3-mo -4.65%
6-mo -35.94%
1-year -51.19%
3-year -43.06%
5-year -91.09%
YTD -18.00%
2021 -53.49%
2020 70.63%
2019 -37.00%
2018 -72.22%
2017 -43.75%

Continue Researching NAVB

Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:

Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8821 seconds.